167 related articles for article (PubMed ID: 18619980)
1. Pre-clinical evidence for altered absorption and biliary excretion of irinotecan (CPT-11) in combination with quercetin: possible contribution of P-glycoprotein.
Bansal T; Awasthi A; Jaggi M; Khar RK; Talegaonkar S
Life Sci; 2008 Aug; 83(7-8):250-9. PubMed ID: 18619980
[TBL] [Abstract][Full Text] [Related]
2. Effect of P-glycoprotein inhibitor, verapamil, on oral bioavailability and pharmacokinetics of irinotecan in rats.
Bansal T; Mishra G; Jaggi M; Khar RK; Talegaonkar S
Eur J Pharm Sci; 2009 Mar; 36(4-5):580-90. PubMed ID: 19135530
[TBL] [Abstract][Full Text] [Related]
3. Food-drug interaction of (-)-epigallocatechin-3-gallate on the pharmacokinetics of irinotecan and the metabolite SN-38.
Lin LC; Wang MN; Tsai TH
Chem Biol Interact; 2008 Aug; 174(3):177-82. PubMed ID: 18579105
[TBL] [Abstract][Full Text] [Related]
4. Biliary transport of irinotecan and metabolites in normal and P-glycoprotein-deficient mice.
Iyer L; RamÃrez J; Shepard DR; Bingham CM; Hossfeld DK; Ratain MJ; Mayer U
Cancer Chemother Pharmacol; 2002 Apr; 49(4):336-41. PubMed ID: 11914914
[TBL] [Abstract][Full Text] [Related]
5. Effect of P-glycoprotein modulator, cyclosporin A, on the gastrointestinal excretion of irinotecan and its metabolite SN-38 in rats.
Arimori K; Kuroki N; Hidaka M; Iwakiri T; Yamsaki K; Okumura M; Ono H; Takamura N; Kikuchi M; Nakano M
Pharm Res; 2003 Jun; 20(6):910-7. PubMed ID: 12817897
[TBL] [Abstract][Full Text] [Related]
6. Active transepithelial transport of irinotecan (CPT-11) and its metabolites by human intestinal Caco-2 cells.
Yamamoto W; Verweij J; de Bruijn P; de Jonge MJ; Takano H; Nishiyama M; Kurihara M; Sparreboom A
Anticancer Drugs; 2001 Jun; 12(5):419-32. PubMed ID: 11395570
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetic modulation of irinotecan metabolites by sulphobromophthalein in rats.
Itoh T; Itagaki S; Sasaki K; Hirano T; Takemoto I; Iseki K
J Pharm Pharmacol; 2004 Jun; 56(6):809-12. PubMed ID: 15231047
[TBL] [Abstract][Full Text] [Related]
8. Cetuximab increases concentrations of irinotecan and of its active metabolite SN-38 in plasma and tumour of human colorectal carcinoma-bearing mice.
Chu C; Abbara C; Tandia M; Polrot M; Gonin P; Farinotti R; Bonhomme-Faivre L
Fundam Clin Pharmacol; 2014 Dec; 28(6):652-60. PubMed ID: 24588516
[TBL] [Abstract][Full Text] [Related]
9. Multiplicity of biliary excretion mechanisms for the camptothecin derivative irinotecan (CPT-11), its metabolite SN-38, and its glucuronide: role of canalicular multispecific organic anion transporter and P-glycoprotein.
Sugiyama Y; Kato Y; Chu X
Cancer Chemother Pharmacol; 1998; 42 Suppl():S44-9. PubMed ID: 9750028
[TBL] [Abstract][Full Text] [Related]
10. Improvement of oral efficacy of Irinotecan through biodegradable polymeric nanoparticles through in vitro and in vivo investigations.
Ahmad N; Alam MA; Ahmad R; Umar S; Jalees Ahmad F
J Microencapsul; 2018 Jun; 35(4):327-343. PubMed ID: 29873288
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetic modulation of irinotecan and metabolites by cyclosporin A.
Gupta E; Safa AR; Wang X; Ratain MJ
Cancer Res; 1996 Mar; 56(6):1309-14. PubMed ID: 8640819
[TBL] [Abstract][Full Text] [Related]
12. Pre-clinical evidence of enhanced oral bioavailability of the P-glycoprotein substrate talinolol in combination with morin.
Pathak SM; Udupa N
Biopharm Drug Dispos; 2010 Mar; 31(2-3):202-14. PubMed ID: 20238375
[TBL] [Abstract][Full Text] [Related]
13. A mechanistic study on reduced toxicity of irinotecan by coadministered thalidomide, a tumor necrosis factor-alpha inhibitor.
Yang XX; Hu ZP; Xu AL; Duan W; Zhu YZ; Huang M; Sheu FS; Zhang Q; Bian JS; Chan E; Li X; Wang JC; Zhou SF
J Pharmacol Exp Ther; 2006 Oct; 319(1):82-104. PubMed ID: 16815871
[TBL] [Abstract][Full Text] [Related]
14. Intra-herb pharmacokinetics interaction between quercetin and isorhamentin.
Lan K; He JL; Tian Y; Tan F; Jiang XH; Wang L; Ye LM
Acta Pharmacol Sin; 2008 Nov; 29(11):1376-82. PubMed ID: 18954533
[TBL] [Abstract][Full Text] [Related]
15. Effect of P-glycoprotein modulators on the pharmacokinetics of camptothecin using microdialysis.
Tsai TH; Lee CH; Yeh PH
Br J Pharmacol; 2001 Nov; 134(6):1245-52. PubMed ID: 11704644
[TBL] [Abstract][Full Text] [Related]
16. Involvement of up-regulation of hepatic breast cancer resistance protein in decreased plasma concentration of 7-ethyl-10-hydroxycamptothecin (SN-38) by coadministration of S-1 in rats.
Yokoo K; Hamada A; Watanabe H; Matsuzaki T; Imai T; Fujimoto H; Masa K; Imai T; Saito H
Drug Metab Dispos; 2007 Sep; 35(9):1511-7. PubMed ID: 17537871
[TBL] [Abstract][Full Text] [Related]
17. P-glycoprotein inhibition by the multidrug resistance-reversing agent MS-209 enhances bioavailability and antitumor efficacy of orally administered paclitaxel.
Kimura Y; Aoki J; Kohno M; Ooka H; Tsuruo T; Nakanishi O
Cancer Chemother Pharmacol; 2002 Apr; 49(4):322-8. PubMed ID: 11914912
[TBL] [Abstract][Full Text] [Related]
18. P-glycoprotein is responsible for the poor intestinal absorption and low toxicity of oral aconitine: in vitro, in situ, in vivo and in silico studies.
Yang C; Zhang T; Li Z; Xu L; Liu F; Ruan J; Liu K; Zhang Z
Toxicol Appl Pharmacol; 2013 Dec; 273(3):561-8. PubMed ID: 24120885
[TBL] [Abstract][Full Text] [Related]
19. In vitro to in vivo evidence of the inhibitor characteristics of Schisandra lignans toward P-glycoprotein.
Liang Y; Zhou Y; Zhang J; Liu Y; Guan T; Wang Y; Xing L; Rao T; Zhou L; Hao K; Xie L; Wang GJ
Phytomedicine; 2013 Aug; 20(11):1030-8. PubMed ID: 23731657
[TBL] [Abstract][Full Text] [Related]
20. Nano scale self-emulsifying oil based carrier system for improved oral bioavailability of camptothecin derivative by P-Glycoprotein modulation.
Negi LM; Tariq M; Talegaonkar S
Colloids Surf B Biointerfaces; 2013 Nov; 111():346-53. PubMed ID: 23850745
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
